EIP Pharma

John Alam is President and CEO of EIP Pharma.

Until May 2014, he was therapeutic area head for diseases of aging within Sanofi R&D. In that role he led global R&D activities at Sanofi directed at Alzheimer’s disease and Parkinson’s disease, as well as number of other age-related diseases.

Previously, from 1997 until 2008 he held positions of increasingly responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and EVP, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. And, from 1991 to 1997, while at Biogen, Inc, he led the clinical development of Avonex (interferon beta-1a) for the treatment of multiple sclerosis.

John is currently also on the board of directors for Alliance for Aging Research (Washington DC) and was previously on the Board of Trustees of Accelerated Cure Project for Multiple Sclerosis (Waltham MA). He is also currently on the advisory council of the Board of Overseers of WGBH (Boston MA).

John received a S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Subsequently, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.